Missouri 2023 Regular Session

Missouri House Bill HB117

Introduced
1/4/23  
Refer
2/9/23  
Report Pass
2/28/23  
Refer
3/2/23  
Report Pass
3/6/23  
Engrossed
3/22/23  
Refer
4/6/23  

Caption

Modifies provisions relating to controlled substances

Impact

The implementation of HB 117 is expected to significantly enhance the response to opioid-related emergencies throughout the state. By allowing qualified first responders to administer naloxone, the bill aims to decrease the incidence of overdose fatalities. Additionally, it enables pharmacists to dispense opioid antagonists under standing orders, thus making these medications more accessible. The financial implications of the legislation include the establishment of a dedicated fund for opioid addiction treatment, funded by settlement proceeds from lawsuits related to opioid manufacturers and distributors, ensuring that the resources are strictly allocated to addiction treatment services.

Summary

House Bill 117 aims to modify the provisions relating to controlled substances, particularly focusing on opioid antagonists and addiction mitigation medications. The bill proposes the repeal of certain sections from existing law while establishing new sections that define the roles of qualified first responders, pharmacists, and the state in addressing opioid overdoses and addiction. Notably, it emphasizes the administration and dispensing of naloxone, an opioid antagonist, by trained first responders and licensed pharmacists, expanding the availability of this life-saving medication to individuals at risk of overdose.

Contention

While the bill has garnered widespread support due to the pressing need for effective responses to the opioid crisis, some concerns have been raised. Critics argue that the focus on naloxone administration may overshadow comprehensive strategies for addiction treatment and prevention. There are worries that without sufficient education and resources, the widespread availability of naloxone could lead to its misuse or create a false sense of security among those at risk. Still, proponents assert that increasing access to naloxone is a critical step in saving lives and that other forms of treatment can be integrated into broader public health initiatives.

Companion Bills

No companion bills found.

Previously Filed As

MO SB45

Modifies provisions relating to health care

MO HB2162

Modifies provisions relating to the opioid addiction treatment and recovery fund

MO SB690

Modifies provisions of law relating to health care

MO SB1037

Modifies provisions relating to naltrexone hydrochloride

MO SB325

Controlled substances: fentanyl.

MO SB186

Modifies provisions relating to public safety

MO SB1502

Controlled substances: xylazine.

MO SB6

Controlled substances: xylazine.

MO SB24

Creates new provisions relating to vulnerable persons

MO H5615

Revises sections of the uniform controlled substances act to remove specific opioid dosage requirements, revises the uniform controlled substances act in accordance with current standards of professional practice and would repeal chapter 37.4 of title 5.

Similar Bills

MS HB1137

Opioid antagonists; authorize community organizations and others to receive and administer.

CA AB1341

Public health: oral therapeutics.

MN HF1197

Licensed pharmacist authority expanded to initiate, order, and administer vaccines and medical and laboratory tests; and medical assistance coverage required.

MN SF1176

Licensed pharmacists authority to initiate, order and administer vaccines and certain medical and laboratory tests; coverage under medical assistance requirement

MS HB791

Pharmacists; authorize to test for and administer treatment for minor, nonchronic health conditions.

MS HB1317

Pharmacists; authorize to test for and administer treatment for minor, nonchronic health conditions.

MS SB2675

Pharmacists; authorize to test for and administer treatment for minor, nonchronic health conditions.

MS HB252

Pharmacists; authorize to test for and administer treatment for minor, nonchronic health conditions.